Gonasi Kit (Human Chorionic Gonadotropin)

Gonasi Kit is indicated for several fertility‑related purposes in assisted reproductive technology.

• Induction of ovulation in women with anovulatory or oligo‑ovulatory disorders.
• Luteal phase support following ovulation induction or embryo transfer.
• Treatment of infertility associated with luteinizing hormone deficiency.
• Adjunct therapy in in‑vitro fertilisation (IVF) cycles to promote follicular development.
• Use in certain male hypogonadism protocols to stimulate endogenous testosterone production (off‑label in some regions).

The safety profile of hCG products such as Gonasi Kit includes both common and less frequent adverse reactions.

Common

• Injection‑site pain, redness, or swelling.
• Headache or mild dizziness.
• Nausea, vomiting, or abdominal discomfort.
• Fluid retention leading to mild edema.
• Breast tenderness or enlargement.

Serious

• Ovarian hyperstimulation syndrome (OHSS) with abdominal distension or rapid weight gain.
• Allergic reactions such as rash, urticaria, or anaphylaxis.
• Thromboembolic events, including deep‑vein thrombosis.
• Ectopic pregnancy risk if ovulation occurs outside the uterus.

Healthcare providers should consider several precautions before prescribing Gonasi Kit to ensure safe use.

• Confirm pregnancy status; avoid use in confirmed pregnancy unless specifically indicated.
• Assess for a history of ovarian cysts, polycystic ovary syndrome, or previous OHSS.
• Evaluate cardiovascular risk factors, especially in patients with a history of thrombosis.
• Monitor thyroid function, as hCG can stimulate thyroid hormone production.
• Use caution in patients with uncontrolled diabetes or adrenal insufficiency.
• Ensure proper injection technique to reduce local reactions.

Gonasi Kit may interact with other medications or substances that affect hormonal balance or coagulation.

Avoid

• Concurrent use of other gonadotropins or LH‑releasing agents without specialist guidance.
• Estrogen‑containing contraceptives during ovulation induction protocols.
• Anticoagulant therapy (e.g., warfarin) in patients at high risk for OHSS.

Use with caution

• Thyroid hormone replacement, as hCG can alter thyroid hormone levels.
• Insulin or oral hypoglycemic agents, due to potential changes in glucose metabolism.
• Corticosteroids, which may mask early signs of OHSS.